Treatment of COVID-19 Patients Using Wharton’s Jelly-Mesenchymal Stem Cells

Breve resumen:The purpose of this study is to investigate the potential use of Wharton’s Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.

Condition or diseaseIntervention/treatmentPhase
Use ofCélulas madre for COVID-19 TreatmentBiological: WJ-MSCsPhase 1

Descripción detallada:

COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.

Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.


NBScience

organización de contratos de investigación

terapia con células madre